This suggests that drugs targeting IFN-, IL-1 or IL-6 could potentially be useful for treating patients who do not respond to anti-TNF therapy
The second-biggest concern is regarding side effects
By starting therapy, patients acknowledge that they have discussed potential benefits, risks, and alternatives with a MedClub clinician and agree to ongoing monitoring as recommended
GLP-1 RAs are especially valuable for obese or diabetic hypertensive patients
This widespread receptor distribution has prompted investigation into potential pleiotropic effects, including anti-inflammatory properties that may contribute to their broader clinical benefits in cardiometabolic disease
The same chromatographic procedure was used to evaluate the pharmacokinetics, safety, and tolerability of once-weekly subcutaneous semaglutide [53]